ReviewInternational journal of nanomedicine2025
Implication of Bimodal Magnetic Resonance and Fluorescence Imaging Probes in Advanced Healthcare: Enhancing Disease Diagnosis and Targeted Therapy.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Contrast Agents for Enhanced Bioimaging: A Comprehensive Review.Chembiochem : a European journal of chemical biology · 2026Review
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
- Progress in the Development of Metal-Organic Frameworks (MOFs) for Medical Imaging of Tumors: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Combining Fluorescence and Magnetic Resonance Imaging in Drug Discovery-A Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular imaging probes hold great promise in disease diagnostics and their therapeutic interventions. However, a single imaging modality sometimes lacks efficiency in all kinds of diseases. Conditions such as cancer, cardiovascular disorders, and neurodegenerative diseases critically require multimodal imaging to characterize complex biological environments accurately. Efficient targeting further enhances probe performance, improving diagnostic precision. This study explores the design rationale and application of bimodal probes designed for Magnetic Resonance (MR) and fluorescence (FL) imaging for their complementary strengths. MRI enables deep tissue visualization, while fluorescence offers high sensitivity and cellular-level resolution. Meticulous attention has been devoted to presenting methodologies aimed at improving the targeting efficacy of these probes. This involves the methodology to enhance targeting efficacy, including ligand-based strategies, nanoparticle functionalization, and molecularly imprinted polymers. The probes combine fluorescence for precise cellular imaging with MRI for in-depth tissue visualization, providing synergistic benefits that elevate their diagnostic potential. Moreover, we offer recent developments in Machine Learning and Artificial Intelligence-based computational approaches for image analysis, enabling more precise diagnosis across a range of diseases that may propel their diagnostic abilities for better therapeutic outcomes. Through systematic analysis and in vitro and in vivo evaluations, we demonstrate the ability of the probes to achieve superior spatial and temporal resolution, facilitating the accurate delineation of biological targets. The integration of these bimodal probes holds great promise for advancing our understanding of complex biological processes, enabling more precise diagnostics, and paving the way for targeted therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.